Immatics appoints new CEO
This article was originally published in Scrip
ImmaticsBiotechnologies (Germany) has appointed Paul Higham chief executive officer, effective August 1st. Mr Higham previously served as director of commercial development at Ark Therapeutics. Before that, he worked as international commercial vice-president for GI, metabolic and pain at Glaxo Wellcome from 1996 to 2001. Immatics is an independent biopharmaceutical company developing active immunotherapies against cancer.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.